Reata Pharmaceuticals, Inc. (RETA) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/10/22
Reata Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results and Provides an Update on Clinical Development ProgramsBusiness Wire • 05/10/22
Reata Pharmaceuticals, Inc. to Report First Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on May 10, 2022Business Wire • 05/02/22
Reata Pharmaceuticals Completes Rolling Submission of New Drug Application for Omaveloxolone for the Treatment of Patients with Friedreich's AtaxiaBusiness Wire • 03/31/22
Reata Pharmaceuticals, Inc. (RETA) Up 3.9% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 03/30/22
Reata Pharmaceuticals, Inc. (RETA) Stock Jumps 14.5%: Will It Continue to Soar?Zacks Investment Research • 03/30/22
Moore Kuehn, PLLC Encourages Investors of Reata Pharmaceuticals, Inc. to Contact Law FirmNewsfile Corp • 03/16/22
Reata Pharmaceuticals Inc.'s (RETA) CEO Warren Huff on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/28/22
Reata Pharmaceuticals, Inc. (RETA) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 02/28/22
Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results and Provides an Update on Clinical Development ProgramsBusiness Wire • 02/28/22
Reata Pharmaceuticals Receives Complete Response Letter From The FDA for Bardoxolone for the Treatment of Patients with Chronic Kidney Disease Caused by Alport SyndromeBusiness Wire • 02/25/22
Earnings Preview: Reata Pharmaceuticals, Inc. (RETA) Q4 Earnings Expected to DeclineZacks Investment Research • 02/21/22
FINAL DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, Encourages Reata Pharmaceuticals, Inc. Investors with Losses Over $100K to Secure Counsel Before Important February 18 Deadline in Securities Class Action - RETANewsfile Corp • 02/18/22
RETA SHAREHOLDER ALERT: Jakubowitz Law Reminds Reata Shareholders of a Lead Plaintiff Deadline of February 18, 2022PRNewsWire • 02/18/22
RETA DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Reata Pharmaceuticals, Inc. Investors to Secure Counsel Before Important February 18 Deadline in Securities Class Action - RETAPRNewsWire • 02/18/22
Reata Pharmaceuticals, Inc. To Report Fourth Quarter and Full Year 2021 Financial Results and To Provide an Update on Development Programs on February 28, 2022Business Wire • 02/18/22
RETA INVESTOR ALERT: Thornton Law Firm Reminds Reata Pharmaceuticals Investors of Important Deadline for Securities Class Action LawsuitNewsfile Corp • 02/17/22
RETA INVESTOR DEADLINE TOMRROW: Hagens Berman, National Trial Attorneys, Encourages Reata Pharmaceuticals (RETA) Investors with Losses to Contact Firm's Attorneys NowNewsfile Corp • 02/17/22
Deadline Tomorrow Alert: The Schall Law Firm Encourages Investors in Reata Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 02/17/22